Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).

Mohammad Asad(Wayne State University), Misako Nagasaka(University of California, Irvine), Luis E. Raez(Florida International University), Hirva Mamdani(Wayne State University), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), W. Michael Korn(Itasca Community College), Stephen V. Liu(Georgetown University), Mohammed Najeeb Al Hallak(The Barbara Ann Karmanos Cancer Institute), C. Patrick(Penn State Milton S. Hershey Medical Center), Sonam Puri(University of Utah), Gilberto Lopes(University of Miami), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), Michael J. Demeure(Hoag Memorial Hospital Presbyterian), Joanne Xiu(Caris Life Sciences (United States)), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Bing Xia(Rutgers, The State University of New Jersey), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Chul Kim(Georgetown University), Hossein Borghaei(Fox Chase Cancer Center)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.e20533
Cited by 1

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k